HUP0300188A2 - Karbonsavszármazékok, mint IP-antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Karbonsavszármazékok, mint IP-antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0300188A2 HUP0300188A2 HU0300188A HUP0300188A HUP0300188A2 HU P0300188 A2 HUP0300188 A2 HU P0300188A2 HU 0300188 A HU0300188 A HU 0300188A HU P0300188 A HUP0300188 A HU P0300188A HU P0300188 A2 HUP0300188 A2 HU P0300188A2
- Authority
- HU
- Hungary
- Prior art keywords
- independently
- compounds
- case
- antagonists
- preparation
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 101100379079 Emericella variicolor andA gene Chemical group 0.000 abstract 1
- 108091006335 Prostaglandin I receptors Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Surgery (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
A találmány általában IP receptor antagonistaként felhasználható (I)általános képletű vegyületekre, az egyedi izomerekre, az izomerekracém vagy nemracém keverékeire, továbbá e vegyületek gyógyászatilagalkalmas sóira vagy szolvátjaira vonatkozik. A képletben R1, R2 és R3jelentése egymástól függetlenül mindenesetben arilcsoport vagyheteroaril-csoport; R4 jelentése karboxil- vagy tetrazolil-csoport; ésA jelentése egymástól függetlenül minden esetben egyeskötés, -O(CH2)p-, -S(CH2)p-; -NR1(CH2)p, -(CH2)pO-, -O(CH2)pO-, -(CH2)p-O(CH2)p-, -(CH2)n-CO(CH2)n-, -CONH-, -(CH2)p-, -HC=CH- vagy -C<C-. Bjelentése egymástól függetlenül minden esetben -(CH2)q-, -CH2O-, -CH2OCH2 vagy -CH2NH-; m, p és q jelentése egymástól függetlenül mindenesetben 1, 2 vagy 3; n és r értéke minden esetben egymástólfüggetlenül 0, 1, 2 vagy 3. A találmány továbbá e vegyületekettartalmazó gyógyszerkészítményekre és ezeknek a vegyületeknek azelőállítására és gyógyászati alkalmazására vonatkozik. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19012900P | 2000-03-16 | 2000-03-16 | |
US24712900P | 2000-11-10 | 2000-11-10 | |
PCT/EP2001/002597 WO2001068591A1 (en) | 2000-03-16 | 2001-03-08 | Carboxylic acid derivatives as ip antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0300188A2 true HUP0300188A2 (hu) | 2003-06-28 |
HUP0300188A3 HUP0300188A3 (en) | 2004-07-28 |
Family
ID=26885804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0300188A HUP0300188A3 (en) | 2000-03-16 | 2001-03-08 | Carboxylic acid derivatives as ip antagonists, process for their preparation and pharmaceutical compositions containing them |
Country Status (22)
Country | Link |
---|---|
US (3) | US6693098B2 (hu) |
EP (1) | EP1265853A1 (hu) |
JP (1) | JP3938689B2 (hu) |
KR (1) | KR100523119B1 (hu) |
CN (1) | CN1241909C (hu) |
AR (1) | AR028252A1 (hu) |
AU (2) | AU5216801A (hu) |
BR (1) | BR0109235A (hu) |
CA (1) | CA2401502C (hu) |
CZ (1) | CZ20023422A3 (hu) |
HK (1) | HK1054924A1 (hu) |
HR (1) | HRP20020733A2 (hu) |
HU (1) | HUP0300188A3 (hu) |
IL (1) | IL151478A (hu) |
MA (1) | MA27679A1 (hu) |
MX (1) | MXPA02008931A (hu) |
NO (1) | NO328526B1 (hu) |
NZ (1) | NZ521028A (hu) |
PL (1) | PL207869B1 (hu) |
RU (1) | RU2268258C2 (hu) |
WO (1) | WO2001068591A1 (hu) |
YU (1) | YU68102A (hu) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2268258C2 (ru) * | 2000-03-16 | 2006-01-20 | Ф.Хоффманн-Ля Рош Аг | Производные карбоновых кислот в качестве антагонистов ip |
MXPA03007865A (es) | 2001-03-02 | 2003-12-04 | Hoffmann La Roche | Derivados de acido alcoxicarbonilamino benzoico y alcoxicarbonilamino tetrazolil fenilo como antagonistas ip. |
CA2438813C (en) | 2001-03-02 | 2008-07-29 | F. Hoffmann-La Roche Ag | Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as ip antagonists |
CN1293042C (zh) * | 2002-02-07 | 2007-01-03 | 远藤仁 | 芳香族氨基酸衍生物及其药物组合物 |
GB2389580A (en) * | 2002-06-12 | 2003-12-17 | Bayer Ag | 2-Naphthamide PGI2 antagonists |
GB2389582A (en) * | 2002-06-13 | 2003-12-17 | Bayer Ag | Pharmaceutically active carboxamides |
KR20050074571A (ko) * | 2002-11-11 | 2005-07-18 | 바이엘 헬스케어 아게 | Ip 수용체 길항제로서의 페닐 또는 헤테로아릴 아미노알칸 유도체 |
ATE524741T1 (de) * | 2002-12-19 | 2011-09-15 | Scripps Research Inst | Zusammensetzungen und verwendungen zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung |
WO2004069805A1 (en) * | 2003-02-10 | 2004-08-19 | Bayer Healthcare Ag | Bis(hetero)aryl carboxamide derivatives for use as pgi2 antagonists |
US20060171945A1 (en) * | 2003-02-14 | 2006-08-03 | Critchley Hilary Octavia D | Ip receptor antagonists for the treatment of pathological uterine conditions |
DE10332560B4 (de) * | 2003-07-11 | 2010-07-08 | Chiracon Gmbh | Verfahren zur Herstellung von ß- Heteroaryl-2-alanin-Verbindungen über 2-Amino-2-(heteroarylmethyl)-carbonsäure-Verbindungen |
US7256207B2 (en) * | 2003-08-20 | 2007-08-14 | Irm Llc | Inhibitors of cathepsin S |
JP2007538103A (ja) * | 2004-05-20 | 2007-12-27 | ザ スクリップス リサーチ インスティテュート | トランスサイレチン安定化 |
WO2006029735A1 (en) * | 2004-09-15 | 2006-03-23 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with prostaglandin 12 receptor (ptgir) |
CA2645099A1 (en) * | 2006-03-24 | 2007-10-04 | Wyeth | Methods for modulating bladder function |
WO2008034016A2 (en) * | 2006-09-15 | 2008-03-20 | Foldrx Pharmaceuticals, Inc. | Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins |
TWI449040B (zh) * | 2006-10-06 | 2014-08-11 | Crocus Technology Sa | 用於提供內容可定址的磁阻式隨機存取記憶體單元之系統及方法 |
KR20230085944A (ko) * | 2008-03-18 | 2023-06-14 | 아레나 파마슈티칼스, 인크. | 프로스타시클린 (pgi2) 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제 |
ATE538474T1 (de) * | 2008-04-07 | 2012-01-15 | Crocus Technology Sa | System und verfahren zum schreiben von daten auf magnetoresistive direktzugriffsspeicherzellen |
EP2124228B1 (en) * | 2008-05-20 | 2014-03-05 | Crocus Technology | Magnetic random access memory with an elliptical junction |
US8031519B2 (en) * | 2008-06-18 | 2011-10-04 | Crocus Technology S.A. | Shared line magnetic random access memory cells |
GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
LT2593452T (lt) * | 2010-07-14 | 2017-04-10 | Novartis Ag | Heterocikliniai junginiai, kaip ip receptoriaus agonistai |
EP2609075B1 (en) * | 2010-08-23 | 2016-03-16 | Novartis AG | Process for the preparation of intermediates for the manufacture of nep inhibitors |
WO2013038351A1 (en) | 2011-09-16 | 2013-03-21 | Pfizer Inc. | Solid forms of a transthyretin dissociation inhibitor |
JP6073923B2 (ja) * | 2012-01-13 | 2017-02-01 | ノバルティス アーゲー | 肺動脈高血圧症(pah)および関連障害の治療のためのip受容体アゴニストとしての縮合ピロール |
WO2014143592A1 (en) | 2013-03-12 | 2014-09-18 | Allergan, Inc. | Inhibition of neovascularization by inhibition of prostanoid ip receptors |
WO2014143591A1 (en) | 2013-03-12 | 2014-09-18 | Allergan, Inc. | Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors |
WO2017019175A1 (en) * | 2015-07-24 | 2017-02-02 | Newlink Genetics Corporation | Salts and prodrugs of 1-methyl-d-tryptophan |
KR20220119169A (ko) | 2017-03-01 | 2022-08-26 | 아레나 파마슈티칼스, 인크. | Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법 |
PE20210367A1 (es) | 2018-02-02 | 2021-02-26 | Maverix Oncology Inc | Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina |
CN111408314B (zh) * | 2020-04-17 | 2021-08-10 | 甘肃智仑新材料科技有限公司 | 一种含炔基阳离子表面活性剂及其制备方法 |
KR20230158076A (ko) * | 2021-03-18 | 2023-11-17 | 제니비젼 인크. | 눈 질환을 치료하기 위한 방법 및 조성물 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB895344A (en) | 1957-08-30 | 1962-05-02 | Ciba Ltd | Method of temporary protection of hydroxy, mercapto and amino groups |
US3875207A (en) * | 1967-01-25 | 1975-04-01 | Ciba Geigy Corp | Process for the temporary protection of amino groups in peptide syntheses |
DE1793827A1 (de) | 1967-01-25 | 1976-05-13 | Ciba Geigy Ag | Neue aminoschutzgruppen, ihre verwendung bei peptidsynthesen und verfahren zur herstellung der entsprechend geschuetzten aminosaeuren und peptide |
DE1934783A1 (de) | 1969-07-09 | 1971-01-28 | Bayer Ag | Biphenylisopropyloxycarbonylfluorid und seine Verwendung zur Acylierung von Aminosaeuren |
DE2641060A1 (de) | 1976-09-11 | 1978-03-16 | Hoechst Ag | Beta-lactamverbindungen und verfahren zu ihrer herstellung |
US4145337A (en) * | 1977-10-11 | 1979-03-20 | Hoffmann-La Roche Inc. | Aminoethylglycine containing polypeptides |
JPH0672985B2 (ja) | 1986-05-29 | 1994-09-14 | 株式会社ハツコウ | メガネ枠フイツテイング調整システム |
NZ221729A (en) | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
US5250517A (en) | 1987-10-06 | 1993-10-05 | Hoffmann-La Roche Inc. | Renin inhibiting compounds |
JP3507494B2 (ja) | 1992-08-13 | 2004-03-15 | ワーナー−ランバート・コンパニー | タキキニン拮抗薬 |
JPH0672985A (ja) | 1992-08-28 | 1994-03-15 | Ono Pharmaceut Co Ltd | (チオ)ウレア誘導体 |
JP3118738B2 (ja) | 1992-12-22 | 2000-12-18 | 小野薬品工業株式会社 | (チオ)ウレア誘導体 |
NZ287284A (en) | 1994-06-06 | 1998-10-28 | Warner Lambert Co | N-[2-(phenyl(substituted)ethylamino)-1-(indolylmethyl)-1-methyl -2-oxoethyl] carbamic acid ester derivatives, medicaments and intermediates |
DE19544687A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DK0888292T3 (da) * | 1996-03-20 | 2002-02-18 | Genentech Inc | Tricykliske forbindelser med virkning over for integriner, især alphavbeta3 integriner, fremgangsmåde til deres fremstilling, mellemprodukter deraf, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf |
NZ331480A (en) * | 1997-09-04 | 2000-02-28 | F | 2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions |
RU2268258C2 (ru) * | 2000-03-16 | 2006-01-20 | Ф.Хоффманн-Ля Рош Аг | Производные карбоновых кислот в качестве антагонистов ip |
-
2001
- 2001-03-08 RU RU2002127781/04A patent/RU2268258C2/ru not_active IP Right Cessation
- 2001-03-08 MX MXPA02008931A patent/MXPA02008931A/es active IP Right Grant
- 2001-03-08 YU YU68102A patent/YU68102A/sh unknown
- 2001-03-08 AU AU5216801A patent/AU5216801A/xx active Pending
- 2001-03-08 CN CNB018066321A patent/CN1241909C/zh not_active Expired - Fee Related
- 2001-03-08 AU AU2001252168A patent/AU2001252168B2/en not_active Ceased
- 2001-03-08 WO PCT/EP2001/002597 patent/WO2001068591A1/en active Application Filing
- 2001-03-08 NZ NZ521028A patent/NZ521028A/en not_active IP Right Cessation
- 2001-03-08 CZ CZ20023422A patent/CZ20023422A3/cs unknown
- 2001-03-08 HU HU0300188A patent/HUP0300188A3/hu unknown
- 2001-03-08 KR KR10-2002-7012187A patent/KR100523119B1/ko not_active IP Right Cessation
- 2001-03-08 CA CA2401502A patent/CA2401502C/en not_active Expired - Fee Related
- 2001-03-08 JP JP2001567688A patent/JP3938689B2/ja not_active Expired - Fee Related
- 2001-03-08 EP EP01925395A patent/EP1265853A1/en not_active Withdrawn
- 2001-03-08 BR BR0109235-9A patent/BR0109235A/pt not_active IP Right Cessation
- 2001-03-08 PL PL358216A patent/PL207869B1/pl not_active IP Right Cessation
- 2001-03-14 AR ARP010101179A patent/AR028252A1/es not_active Application Discontinuation
- 2001-03-14 US US09/810,436 patent/US6693098B2/en not_active Expired - Fee Related
-
2002
- 2002-08-26 IL IL151478A patent/IL151478A/en not_active IP Right Cessation
- 2002-09-05 HR HR20020733A patent/HRP20020733A2/hr not_active Application Discontinuation
- 2002-09-12 MA MA26816A patent/MA27679A1/fr unknown
- 2002-09-13 NO NO20024387A patent/NO328526B1/no not_active IP Right Cessation
-
2003
- 2003-05-09 US US10/434,809 patent/US7056903B2/en not_active Expired - Fee Related
- 2003-10-14 HK HK03107345A patent/HK1054924A1/xx not_active IP Right Cessation
-
2005
- 2005-09-30 US US11/240,547 patent/US7312230B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0300188A2 (hu) | Karbonsavszármazékok, mint IP-antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
FI941987A (fi) | Uudet aminohappojohdannaiset, menetelmät niiden valmistamiseksi ja näitä yhdisteitä sisältävät farmaseuttiset koostumukset | |
PL398536A1 (pl) | Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie do leczenia HIV | |
HUP0301195A2 (hu) | Alfa-4 integrin antagonista hatású aza-hidas biciklusos aminosav-származékok és ilyen vegyületeket tartalmazó gyógyszerkészítmények | |
DE59010017D1 (de) | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung | |
EA199800794A1 (ru) | Новые производные арилглициламида, способ их получения и фармацевтическая композиция, содержащая эти соединения | |
HUP0101511A2 (hu) | 1-[(1-Szubsztituált-4-piperidinil)-metil]-4-piperidin-származékok, eljárás a vegyületek előállítására, a vegyületeket tartalmazó gyógyászati készítmények és intermedierjeik | |
EE04911B1 (et) | Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks | |
IL155333A0 (en) | Sulfanilide derivatives for use in medicine, certain such new derivatives and their preparation | |
NO974734D0 (no) | Arylglycinamidderivater, fremgangsmåte for fremstilling av disse forbindelsene og farmasöytiske blandinger inneholdende slike forbindelser | |
YU22996A (sh) | Novi derivati arilglicinamida postupci za njihovo pripremanje i farmaceutski preparati koji sadrže ova jedinjenja | |
NO172580C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte n-(1-alkyl-3-hydroksy-4-piperidinyl)benzamider | |
DE69431069D1 (de) | Cyclische amidderivate als neurokinin a antagonisten | |
NO973652L (no) | 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreseptor-antagonist | |
TNSN97014A1 (fr) | Piperidones, procedes pour leur preparation et compositions pharmaceutiques les contenant. | |
EA200300044A1 (ru) | Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции | |
FI963440A (fi) | Uudet aminohappojohdannaiset, näiden valmistusmenetelmä ja näitä yhdisteitä sisältävät farmaseuttiset seokset | |
HUP9901208A2 (hu) | (R)-5-Bróm-n-(1-etil-4-metil-hexahidro-1H-1,4-diazepin-6-il)-2-metoxi-6-(metil-amino)-3-piridin-karboxamid, eljárás előállítására és ezt a vegyületet tartalmazó gyógyászati készítmény | |
GR1001068B (el) | Νέον παράγωγον 5Η-βενζοδιαζεπίνης, φαρμακευτικαί συν?έσεις περιέχουσαι τούτο, και μέ?οδος δια την παρασκευήν αυτών. | |
TR200103473T2 (tr) | Kristalli azabisiklo (2.2.2) oktan-3-amin sitratin polimorfları ve farmasötik kompozisyonları. | |
HUP0203650A2 (hu) | Heterociklusos származékok, eljárás az előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0000307A2 (hu) | Y Neuropeptid antagonisták és ezeket tartalmazó gyógyászati készítmények | |
HUP0401895A2 (hu) | Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0004177A2 (hu) | 4,5-Diaril-oxazol származékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
CA2426221A1 (en) | New neurokinin antagonists, processes for preparing them and pharmaceutical compositions containing these compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |